Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Acta Pharmacol Sin. 2013 Jun;34(6):747-54. doi: 10.1038/aps.2013.50.
Mesenchymal stem cells (MSCs), the major stem cells for cell therapy, have been used in the clinic for approximately 10 years. From animal models to clinical trials, MSCs have afforded promise in the treatment of numerous diseases, mainly tissue injury and immune disorders. In this review, we summarize the recent opinions on methods, timing and cell sources for MSC administration in clinical applications, and provide an overview of mechanisms that are significant in MSC-mediated therapies. Although MSCs for cell therapy have been shown to be safe and effective, there are still challenges that need to be tackled before their wide application in the clinic.
间充质干细胞（MSCs）是细胞治疗的主要干细胞，已经在临床上应用了大约 10 年。从动物模型到临床试验，MSCs 在治疗许多疾病方面都有希望，主要是组织损伤和免疫紊乱。在这篇综述中，我们总结了最近关于 MSC 临床应用中给药方法、时间和细胞来源的意见，并概述了在 MSC 介导的治疗中具有重要意义的机制。尽管细胞治疗用 MSCs 已被证明是安全有效的，但在其广泛应用于临床之前，仍需要解决一些挑战。
